ALPINE IMMUNE SCIENCES, INC. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/37bd85ea-8b5a-49bd-89a2-0a4a80350eb0/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2023 | $58.9M | 2023-01-01 – 2023-12-31 | evidence 0001626199-24-000048 |
| FY 2022 | $30.1M | 2022-01-01 – 2022-12-31 | evidence 0001626199-23-000037 |
| FY 2021 | $23.4M | 2021-01-01 – 2021-12-31 | evidence 0001626199-22-000032 |
| FY 2020 | $9.3M | 2020-01-01 – 2020-12-31 | evidence 0001626199-21-000038 |
| FY 2019 | $1.7M | 2019-01-01 – 2019-12-31 | evidence 0001626199-20-000009 |
| FY 2018 | $705.0k | 2018-01-01 – 2018-12-31 | evidence 0001626199-19-000010 |
| FY 2017 | $1.7M | 2017-01-01 – 2017-12-31 | evidence 0001626199-19-000010 |
| FY 2016 | $3.0M | 2016-01-01 – 2016-12-31 | evidence 0001626199-19-000010 |
| FY 2015 | $0 | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-003896 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ALPINE IMMUNE SCIENCES, INC. — all facts · Net Income · Operating Income